Nucleoside Analogues with a 1,3-DieneFe(CO)3 Substructure: Stereoselective Synthesis, Configurational Assignment, and Apoptosis-Inducing Activity
Dr. Christoph Hirschhäuser
Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorDr. Juraj Velcicky
Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorDr. Daniel Schlawe
Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorDr. Erik Hessler
Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorDr. André Majdalani
Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorDr. Jörg-Martin Neudörfl
Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorCorresponding Author
Dr. Dr. Aram Prokop
Children's Hospital Cologne, Department of Paediatric Oncology, Amsterdamer Strasse 59, 50735 Köln (Germany)
Aram Prokop, Children's Hospital Cologne, Department of Paediatric Oncology, Amsterdamer Strasse 59, 50735 Köln (Germany)
Hans-Günther Schmalz, Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorDr. Thomas Wieder
Department of Dermatology, University Medical Center Tübingen, Liebermeisterstrasse 25, 72076 Tübingen (Germany)
Search for more papers by this authorCorresponding Author
Prof. Dr. Hans-Günther Schmalz
Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Aram Prokop, Children's Hospital Cologne, Department of Paediatric Oncology, Amsterdamer Strasse 59, 50735 Köln (Germany)
Hans-Günther Schmalz, Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorDr. Christoph Hirschhäuser
Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorDr. Juraj Velcicky
Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorDr. Daniel Schlawe
Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorDr. Erik Hessler
Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorDr. André Majdalani
Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorDr. Jörg-Martin Neudörfl
Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorCorresponding Author
Dr. Dr. Aram Prokop
Children's Hospital Cologne, Department of Paediatric Oncology, Amsterdamer Strasse 59, 50735 Köln (Germany)
Aram Prokop, Children's Hospital Cologne, Department of Paediatric Oncology, Amsterdamer Strasse 59, 50735 Köln (Germany)
Hans-Günther Schmalz, Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorDr. Thomas Wieder
Department of Dermatology, University Medical Center Tübingen, Liebermeisterstrasse 25, 72076 Tübingen (Germany)
Search for more papers by this authorCorresponding Author
Prof. Dr. Hans-Günther Schmalz
Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Aram Prokop, Children's Hospital Cologne, Department of Paediatric Oncology, Amsterdamer Strasse 59, 50735 Köln (Germany)
Hans-Günther Schmalz, Department of Chemistry, University of Cologne, Greinstrasse 4, 50939 Köln (Germany), Fax: (+49) 221-470-3064
Search for more papers by this authorGraphical Abstract
I gotta Fe-ling: Iron-containing nucleoside analogues, which were first synthesized during an exercise in stereoselective π-complex chemistry, exhibited pronounced cytotoxic and apoptosis-inducing activities, even against resistant cancer cell lines. Both hetero- (X=O) and carbocyclic (X=CH2) compounds were studied, and a synthetic route to R′-labeled derivatives was developed as a precondition for future biological experiments. TDS=thexyldimethylsilyl.
Abstract
The synthesis and stereochemical assignment of two classes of iron-containing nucleoside analogues, both of which contain a butadieneFe(CO)3 substructure, is described. The first type of compounds are Fe(CO)3-complexed 3′-alkenyl-2′,3′-dideoxy-2′,3′-dehydro nucleosides (2,5-dihydrofuran derivatives), from which the second class of compounds is derived by formal replacement of the ring oxygen atom by a CH2 group (carbocyclic nucleoside analogues). These compounds were prepared in a stereoselective manner through the metal-assisted introduction of the nucleobase. Whilst the furanoid intermediates were prepared from carbohydrates (such as methyl-glucopyranoside), the carbocyclic compounds were obtained by using an intramolecular Pauson–Khand reaction. Stereochemical assignments based on NMR and CD spectroscopy were confirmed by X-ray structural analysis. Biological investigations revealed that several of the complexes exhibited pronounced apoptosis-inducing properties (through an unusual caspase 3-independent but ROS-dependent pathway). Furthermore, some structure–activity relationships were identified, also as a precondition for the design and synthesis of fluorescent and biotin-labeled conjugates.
Supporting Information
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Filename | Description |
---|---|
chem_201301672_sm_miscellaneous_information.pdf1.6 MB | miscellaneous_information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1For a “tutorial review” on bioorganic chemistry, see:
- 1aC. G. Hartinger, P. J. Dyson, Chem. Soc. Rev. 2009, 38, 391–401; For recent reviews, see:
- 1bE. A. Hillard, G. Jaouen, Organometallics 2011, 30, 20–27;
- 1cR. H. Fish, Aust. J. Chem. 2010, 63, 1505–1513;
- 1dM. Patra, G. Gasser, ChemBioChem 2012, 13, 1232–1252;
- 1eR. H. Fish, G. Jaouen, Organometallics 2003, 22, 2166–2177; W. Beck, K. Severin, Chem. Unserer Zeit 2002, 36, 356–365;
- 1fN. Chavain, C. Biot, Curr. Med. Chem. 2010, 17, 2729–2745;
- 1gE. Meggers, Chem. Commun. 2009, 1001–1010;
- 1hG. Gasser, N. Metzler-Nolte, Curr. Opin. Chem. Biol. 2012, 16, 84–91.
- 2E. Hillard, A. Vessieres, L. Thouin, G. Jaouen, C. Amatore, Angew. Chem. 2006, 118, 291–296;
10.1002/ange.200502925 Google ScholarAngew. Chem. Int. Ed. 2006, 45, 285–290.
- 3C. Biot, D. Taramelli, I. Forfar-Bares, L. A. Maciejewski, M. Boyce, G. Nowogrocki, J. S. Brocard, N. Basilico, P. Olliaro, T. J. Egan, Mol. Pharmaceutics 2005, 2, 185–193.
- 4For examples of dicobalt complexes, see:
- 4aI. Ott, B. Kircher, R. Dembinski, R. Gust, Expert Opin. Ther. Patents 2008, 18, 327–337; for ferrocene-based compounds, see:
- 4bD. R. van Staveren, N. Metzler-Nolte, Chem. Rev. 2004, 104, 5931–5985; for compounds with anticancer activity, see:
- 4cI. Ott, R. Gust, Arch. Pharm. 2007, 340, 117–126;
- 4dG. Gasser, I. Ott, N. Metzler-Nolte, J. Med. Chem. 2011, 54, 3–25;
- 4eJ. Mattsson, P. Govindaswamy, A. K. Renfrew, P. J. Dyson, P. Stepnicka, G. Suess-Fink, B. Therrien, Organometallics 2009, 28, 4350–4357;
- 4fG. S. Smith, B. Therrien, Dalton Trans. 2011, 40, 10793–10800; for CO-releasing molecules, see:
- 4gT. Santos-Silva, A. Mukhopadhyay, J. D. Seixas, G. J. L. Bernardes, C. C. Romao, M. J. Romao, Curr. Med. Chem. 2011, 18, 3361–3366;
- 4hW. Huber, R. Linder, J. Niesel, U. Schatzschneider, B. Spingler, P. C. Kunz, Eur. J. Inorg. Chem. 2012, 3140–3146;
- 4iS. Romanski, B. Kraus, U. Schatzschneider, J.-M. Neudörfl, S. Amslinger, H.-G. Schmalz, Angew. Chem. 2011, 123, 2440–2444;
10.1002/ange.201006598 Google ScholarAngew. Chem. Int. Ed. 2011, 50, 2392–2396.
- 5D. Schlawe, A. Majdalani, J. Velcicky, E. Hessler, T. Wieder, A. Prokop, H.-G. Schmalz, Angew. Chem. 2004, 116, 1763–1766;
10.1002/ange.200353132 Google ScholarAngew. Chem. Int. Ed. 2004, 43, 1731–1734.
- 6J. C. Franke, M. Plotz, A. Prokop, C. C. Geilen, H.-G. Schmalz, J. Eberle, Biochem. Pharmacol. 2010, 79, 575–586.
- 7
- 7aA. Prokop, M. Eissmann, P. Jesse, G. Henze, P. James, J. Neudörfl, H. G. Schmalz, H. Lode, Blood 2006, 108, 179B;
- 7bP. James, J. Neudörfl, M. Eissmann, P. Jesse, A. Prokop, H.-G. Schmalz, Org. Lett. 2006, 8, 2763–2766.
- 8
- 8aT. L. Su, B. Bennua, H. Vorbrüggen, H. J. Lindner, Chem. Ber. 1981, 114, 1269–1278;
- 8bH. Vorbrüggen, B. Bennua, Chem. Ber. 1981, 114, 1279–1286;
- 8cH. Vorbrüggen, G. Höfle, Chem. Ber. 1981, 114, 1256–1268;
- 8dH. Vorbrüggen, K. Krolikiewicz, B. Bennua, Chem. Ber. 1981, 114, 1234–1255.
- 9N. Rehnberg, G. Magnusson, J. Org. Chem. 1990, 55, 5467–5476.
- 10H.-G. Schmalz, E. Hessler, J. W. Bats, G. Dürner, Tetrahedron Lett. 1994, 35, 4543–4546.
- 11Whilst good selectivity for the primary hydroxy group was achieved in pyridine, lower selectivity was observed when DMF was employed as the solvent.
- 12Earlier procedures for the synthesis of the epoxide mixture 13 α/14 β (see refs. [9,5]) involved the use of diethyl azodicarboxylate (DEAD) in benzene. As this reaction is an early step in the synthesis of our most-active compounds (e.g., N69), we tested diisopropyl azodicarboxylate (DIAD) in toluene instead, which worked equally well.
- 13We advise the use of freshly distilled TMU, although some batches of commercially available material worked equally well. Frequently observed side reactions led to furan derivatives that resulted from the elimination of corresponding alcohols, as well as uncharacterized polymerization products.
- 14D. R. Brittelli, J. Org. Chem. 1981, 46, 2514–2520.
- 15For a review on selective π complexation, see: R. S. Paley, Chem. Rev. 2002, 102, 1493–1524.
- 16Although the observed diastereoselectivity in the complexation of compound 16 β is higher than those of compounds 10 and 11, it is reasonable to attribute this difference to the different alkoxy substituents (R3; 10 and 11: R3α=OBn, 16 α: R3α=OMe). The synthesis of the corresponding methoxy derivatives of compounds 10 and 11 was attempted, but the ring-contraction/condensation reaction (c.f. 8→9) was not successful in this case.
- 17E. Hessler, H.-G. Schmalz, G. Dürner, Tetrahedron Lett. 1994, 35, 4547–4550.
- 18A. Pfletschinger, H.-G. Schmalz, W. Koch, Eur. J. Inorg. Chem. 1999, 1869–1880.
10.1002/(SICI)1099-0682(199911)1999:11<1869::AID-EJIC1869>3.0.CO;2-2 CASWeb of Science®Google Scholar
- 19The demand for an excess of Lewis acid can be attributed to a buffering effect of the silylated nucleobase.
- 20R. L. Schilsky, Oncology 2000, 14, 1297–1306.
- 21F. Djedaini, D. Gree, J. Martelli, R. Gree, L. Leroy, J. Bolard, L. Toupet, Tetrahedron Lett. 1989, 30, 3781–3784.
- 22The stability of compound 32 β against aqueous acid (HCl, pH 2) was evaluated. Therefore, compound 32 β was stirred in HCl (0.01 M) at 37 °C. The concentration of compound 32 β was monitored by HPLC after 10, 100, and 300 min and degradation half-lives of approximately 1 h were determined.
- 23For an account of the increased resistance of carbocyclic nucleoside analogues towards enzymatic cleavage, see:
- 23aC. Desgranges, G. Razaka, M. Rabaud, H. Bricaud, J. Balzarini, E. Declercq, Biochem. Pharmacol. 1983, 32, 3583–3590; for the decrease in toxicity, see:
- 23bR. C. Cookson, P. J. Dudfield, R. F. Newton, P. Ravenscroft, D. I. C. Scopes, J. M. Cameron, Eur. J. Med. Chem. 1985, 20, 375–377;
- 23cM. Ferrero, V. Gotor, Chem. Rev. 2000, 100, 4319–4348;
- 23dO. Arjona, A. M. Gómez, J. C. López, J. Plumet, Chem. Rev. 2007, 107, 1919–2036.
- 24J. Velcicky, A. Lanver, J. Lex, A. Prokop, T. Wieder, H.-G. Schmalz, Chem. Eur. J. 2004, 10, 5087–5110.
- 25
- 25aI. U. Khand, G. R. Knox, P. L. Pauson, W. E. Watts, J. Chem. Soc. D. 1971, 36; selected reviews:
- 25bC. Aubert, L. Fensterbank, P. Garcia, M. Malacria, A. Simonneau, Chem. Rev. 2011, 111, 1954–1993;
- 25cH.-W. Lee, F.-Y. Kwong, Eur. J. Org. Chem. 2010, 789–811; J. Blanco-Urgoiti, L. Anorbe, L. Perez-Serrano, G. Dominguez, J. Perez-Castells, Chem. Soc. Rev. 2004, 33, 32–42;
- 25dK. M. Brummond, J. L. Kent, Tetrahedron 2000, 56, 3263–3283;
- 25eY. K. Chung, Coord. Chem. Rev. 1999, 188, 297–341;
- 25fO. Geis, H.-G. Schmalz, Angew. Chem. 1998, 110, 955–958;
10.1002/(SICI)1521-3757(19980403)110:7<955::AID-ANGE955>3.0.CO;2-T Google ScholarAngew. Chem. Int. Ed. 1998, 37, 911–914; selected reviews on catalytic PKRs:10.1002/(SICI)1521-3773(19980420)37:7<911::AID-ANIE911>3.0.CO;2-O CASPubMedWeb of Science®Google Scholar
- 25gJ. H. Park, K.-M. Chang, Y. K. Chung, Coord. Chem. Rev. 2009, 253, 2461–2480;
- 25hY. Lan, L. Deng, J. Liu, C. Wang, O. Wiest, Z. Yang, Y.-D. Wu, J. Org. Chem. 2009, 74, 5049–5058.
- 26For earlier reports on kinetic resolutions by means of Corey–Bakshi–Shibata (CBS) reduction, see:
- 26aH.-G. Schmalz, H. Jope, Tetrahedron 1998, 54, 3457–3464;
- 26bM. Kurosu, Y. Kishi, J. Org. Chem. 1998, 63, 6100–6101;
- 26cC. Chen, M. E. Layton, S. M. Sheehan, M. D. Shair, J. Am. Chem. Soc. 2000, 122, 7424–7425;
- 26dG. Bringmann, J. Hinrichs, J. Kraus, A. Wuzik, T. Schulz, J. Org. Chem. 2000, 65, 2517–2527;
- 26eP. Dorizon, C. Martin, J.-C. Daran, J.-C. Fiaud, H. B. Kagan, Tetrahedron: Asymmetry 2001, 12, 2625–2630;
- 26fA. D. Lebsack, L. E. Overman, R. J. Valentekovich, J. Am. Chem. Soc. 2001, 123, 4851–4852;
- 26gG. Delogu, D. Fabbri, C. de Candia, A. Patti, S. Pedotti, Tetrahedron: Asymmetry 2002, 13, 891–898.
- 27
- 27aJ.-L. Luche, L. Rodriguez-Hahn, P. Crabbe, J. Chem. Soc. Chem. Commun. 1978, 601–602;
- 27bA. S. Lee, A. W. Norman, W. H. Okamura, J. Org. Chem. 1992, 57, 3846–3854.
- 28The synthesis of the “unnatural” (+)-isomers of the compounds shown in Schemes 10 and 11 proceeded in an analogous manner and is described in the Supporting Information.
- 29Benzoyl (Bz) protection of the cytosine amine atom was necessary for the palladium-catalyzed introduction of the nucleobase (Scheme 8, 51→52).
- 30Deprotection of such substrates has been described with ammonia or alkoxides. Because the use of ammonia was expected to be incompatible with the Fe(CO)3 fragment, we decided in favor of the alkoxide method, by using ethoxide to avoid the formation of transesterification byproducts. See:
- 30aK. Y. Lee, Y. S. Choi, E. Gullen, S. Schlueter-Wirtz, R. F. Schinazi, Y. C. Cheng, C. K. Chu, J. Med. Chem. 1999, 42, 1320–1328;
- 30bA. Holy, Coll. Czech. Chem. Commun. 1993, 58, 649–674.
- 31An interesting (empirical) finding was the higher polarity (by TLC, SiO2) of endo complexes of type 55 compared with their exo counterparts (2).
- 32The release of the cytosolic enzyme LDH into the cell-culture supernatant is indicative of cell-membrane rupture and cell death. LDH release was measured as described previously:
- 32aT. Wieder, C. E. Orfanos, C. C. Geilen, J. Biol. Chem. 1998, 273, 11025–11031; see also: T. Decker, M.-L. Lohmann-Matthes, J. Immunol. Methods 1988, 115, 61–69.
- 33Another noteworthy observation connected to the absolute stereochemistry of these compounds is the sometimes significantly lower cytotoxicity of the racemic material compared to their single enantiomers. This difference may be the consequence of the low solubility of these racemates, which is likely to decrease the “accessible” concentration. For some preliminary data, see the Supporting Information.
- 34
- 34aM. Wilchek, E. A. Bayer, Methods Enzymol. 1990, 184, 5–13;
- 34bM. Wilchek, E. A. Bayer, Methods Enzymol. 1990, 184, 14–45.
- 35A DMAC-labeled N69 derivative with a longer linker was found to be significantly active. The synthesis (through cross-metathesis) afforded a mixture of congeners with scrambled linker length (see the Supporting Information).